A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P, SCarlet RoAD Investigators. · 2017
Read A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. by Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P, SCarlet RoAD Investigators. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5723032.txt.
Description
Ostrowitzki and co-authors report a phase III trial of gantenerumab in prodromal Alzheimer's disease. Gantenerumab is an antibody that binds clumped amyloid-beta and helps clear its plaques. The SCarlet RoAD trial tested whether this early treatment could slow decline.
The trial was randomized, double-blind, and placebo controlled over two years. Of 3,089 people screened, 797 took part and got shots every four weeks. Doses were 105 or 225 milligrams, or a placebo shot. The trial stopped early for futility, with no gain on the main score. Brain imaging side effects rose with dose and with the APOE ε4 gene form. Later checks hinted that higher doses may be needed for a real effect.
Catalog record
| CREATOR | Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P, SCarlet RoAD Investigators. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |